Provectus Biopharmaceuticals, INC

Provectus Biopharmaceuticals provided an update on its clinical development, regulatory, drug discovery, manufacturing, IP, and business development activities at its 2026 Annual Meeting of Stockholders.

Provectus Biopharmaceuticals, Inc. announced an extension of the automatic conversion date for its Series D and D-1 Convertible Preferred Stock to December 31, 2028.

Provectus Biopharmaceuticals, Inc. announced that its stockholders approved all five proposals at the annual meeting on June 18, 2025, including the election of directors, executive compensation, auditor ratification, and authorization for a reverse stock split.

Provectus Biopharmaceuticals, Inc. announced it will provide updates on its clinical development, regulatory affairs, and corporate activities during its annual meeting of stockholders on June 18, 2025.

Provectus Biopharmaceuticals replaced its independent registered public accounting firm from Marcum LLP to CBIZ CPAs P.C. following CBIZ's acquisition of Marcum's attest business.

Provectus Biopharmaceuticals has approved a financing plan to raise up to $10 million through convertible promissory notes to fund its drug development program and general expenses.

Provectus Biopharmaceuticals, Inc. reported its Q2 2026 financial results, highlighting reduced operating expenses but also substantial doubt regarding its ability to continue as a going concern.

Provectus Biopharmaceuticals reported a wider net loss for Q1 2026 compared to the prior year, primarily due to the absence of grant revenue and a decrease in operating expenses.

Provectus Biopharmaceuticals reported a significantly wider net loss in Q3 2025, driven by increased operating expenses and a complete cessation of grant revenue, raising substantial doubt about its ability to continue as a going concern.

Provectus Biopharmaceuticals, Inc. reported a significant increase in net loss for Q2 2025, raising substantial doubt about its ability to continue as a going concern.

Provectus Biopharmaceuticals reports increased operating expenses and net losses for Q1 2025, raising substantial doubt about its ability to continue as a going concern.

Provectus Biopharmaceuticals reports a net loss of $1.01 million for Q3 2024, alongside ongoing efforts to secure additional funding and advance its drug development programs.

Provectus Biopharmaceuticals files an amendment to its 2024 annual report to include previously omitted information regarding directors, executive officers, and corporate governance.

Provectus Biopharmaceuticals details its clinical development programs, intellectual property advancements, and financial strategies in its annual report for the year ended December 31, 2024, while acknowledging substantial doubt about its ability to continue as a going concern.

Provectus Biopharmaceuticals has filed an amendment to its annual report to include required information omitted due to a delay in filing its definitive proxy statement.

Provectus Biopharmaceuticals details its financial status, ongoing research, and intellectual property in its annual 10-K filing, highlighting its clinical-stage development of immunotherapy medicines.

Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, Inc., filed an SEC Form 4 detailing changes in beneficial ownership, including a correction to previously reported Series D-1 Convertible Preferred Stock.

Dominic Rodrigues, Director and President of PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT), reported a transaction involving Series D-1 Convertible Preferred Stock.

John Lacey III reports a conversion of Series D-1 Convertible Preferred Stock into Common Stock at Provectus Biopharmaceuticals, Inc.

Director Bailey Webster reports a conversion of Series D-1 Convertible Preferred Stock into Common Stock.

CEO Edward Pershing converted an 8% unsecured convertible promissory note into 9,436 shares of Series D-1 Preferred Stock.

CEO Edward Pershing acquired a $15,000 8% unsecured convertible promissory note in Provectus Biopharmaceuticals.

Provectus Biopharmaceuticals announces its 2026 Annual Meeting of Stockholders on June 18, 2026, and proposes a reverse stock split to increase its common stock's marketability.

Provectus Biopharmaceuticals, Inc. has announced that its 2025 annual stockholder meeting will be held on June 18, 2025, in Knoxville, Tennessee, with an option for virtual attendance via Zoom Webinar.

Provectus Biopharmaceuticals, Inc. has filed a definitive proxy statement with the SEC.

Provectus Biopharmaceuticals is asking stockholders to approve a reverse stock split and a corresponding reduction in the number of authorized shares to improve marketability and align share structure.

Provectus Biopharmaceuticals will hold its 2024 annual stockholder meeting, including a company update, accessible via Zoom Webinar on June 20, 2024.

Provectus Biopharmaceuticals, Inc. has filed a definitive proxy statement with the SEC.

Edward Pershing amends Schedule 13D, reporting 11.61% beneficial ownership of Provectus Biopharmaceuticals common stock, including convertible notes and options.

Dominic Rodrigues, Vice-Chairman and President of Provectus Biopharmaceuticals, Inc., increased his beneficial ownership to 5.67% through recent stock option grants and preferred stock conversions.

Edward Pershing, Chairman and CEO of Provectus Biopharmaceuticals, increased his beneficial ownership to 10.56% through recent convertible note purchases and conversions.